REPCF News Alert Replicel Life Sciences Inc (REPCF) 0.3077 02/15/2015
Post# of 64074
Posted On: 02/15/2015 11:29:40 AM
Replicel Life Sciences Inc (REPCF) 0.3077 $REPCF
RepliCel Life Sciences to Present at 11th Annual Phacilitate Cell & Gene Therapy Forum in Washington, DC
PR Newswire - Tue Jan 20, 6:00AM CST
RepliCel Life Sciences Inc. (TSX.V: RP) (OTCQB: REPCF), a clinical stage regenerative medicine company focused on the development of autologous cell therapies, announced today that CEO, David Hall, and VP of Business and Corporate Development, Lee Buckler, will both be presenting at Phacilitate Cell & Gene Therapy Forum 2015. The forum will take place January 26-28th, at the Grand Hyatt in Washington, DC. As part of the conference's opening plenary session, Lee Buckler will be co-presenting at 9:20AM (ET) on January 26, a summary of the past year's most notable events in cell and gene therapy as well as a global snapshot of recently approved cell and gene therapy products and late-stage clinical programs. At 4:45PM (ET) on January 26, David Hall will address attendees of the Cell & Gene Therapy track reviewing Japan's national framework of support for the regenerative medicine industry and what that means for foreign cell therapy companies, like RepliCel, actively engaged in doing business with partners in Japan. At 3:10PM (ET) on January 27, Mr. Hall will give a similar presentation to the attendees of the Stem Cells as Discovery & Research Tools track.
RP.VN: 0.380 (-0.005)
RepliCel Life Sciences to Present at Biotech Showcase 2015 in San Francisco
PR Newswire - Wed Jan 07, 7:00AM CST
Meetings focused on investors, analysts, and potential partners for RCS-01 and RCT-01 cell therapies
RP.VN: 0.380 (-0.005)
Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness
PR Newswire - Mon Dec 22, 6:00AM CST
RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: RP), a clinical stage regenerative medicine company focused on the development of autologous cell therapies, announced today the publication of a paper out of the University of Calgary in conjunction with co-authors from Kyoto University and the University of North Carolina, which further validates the company's ongoing clinical research using dermal sheath cup (DSC) cells to reverse the effects of pattern baldness.
RP.VN: 0.380 (-0.005)
RepliCel Life Sciences to Present at World Stem Cell Summit 2014
Marketwired - Tue Dec 02, 7:07AM CST
RepliCel Life Sciences Inc. (TSX VENTURE: RP) (OTCQB: REPCF), a clinical stage regenerative medicine company focused on the development of autologous cell therapies, announces that its Vice President of Business and Corporate Development, R. Lee Buckler, will present updated clinical trial programs for its chronic tendinosis (RCT-A-01), sun damaged and aging skin (RCS-01), and pattern hair loss (RCH-01) products at the World Stem Cell Summit 2014 in San Antonio, Texas on December 4th at 9:00 am (CT) in conference room 3-4 at the Marriott Rivercenter. At other times during the conference, he will also participate in two different panel discussions covering industry-specific topics and lead an industry roundtable discussion.
RP.VN: 0.380 (-0.005)
RepliCel gets go ahead for clinical trial in Canada
Seeking Alpha - at Seeking Alpha - Mon Dec 01, 11:46AM CST
RepliCel Life Sciences Receives Health Canada Clearance for Clinical Trial in Patients with Chronic Achilles Tendinosis
Marketwired - Mon Dec 01, 6:01AM CST
RepliCel Life Sciences Inc. (TSX VENTURE: RP)(OTCQB: REPCF), a clinical stage regenerative medicine company focused on the development of autologous cell therapies, today announced that it has received a No Objection Letter from Health Canada providing its clearance to proceed with the Company's proposed phase 1/2 clinical trial investigating the use of RCT-01 to treat patients suffering from chronic Achilles tendinosis. The study entitled, "A randomized, double-blind, placebo-controlled, single-centre study to evaluate the efficacy and safety of RCT-01 in men and women with unilateral, chronic Achilles tendinosis" (known as the "ReaCT" study), investigates the potential of RCT-01 to treat chronic tendon injury. The ReaCT study has been submitted to the University of British Columbia (UBC) Clinical Ethics Review Board (CREB) for its review and required approval prior to study initiation at the University of British Columbia Hospital.
RP.VN: 0.380 (-0.005)
RepliCel Announces 2014 Third Quarter Financial Results
Marketwired - Wed Nov 26, 6:01AM CST
RepliCel Life Sciences Inc. (the "Company" or "RepliCel"
(TSX VENTURE: RP) (OTCQB: REPCF), a clinical stage regenerative medicine company focused on the development of autologous cell therapies, today announced its operational and financial results for the third quarter ended September 30, 2014. All amounts included in this news release are expressed in Canadian dollars unless otherwise indicated. The Company's financial statements and management report are available at www.sec.gov, www.sedar.com and at www.replicel.com.
RP.VN: 0.380 (-0.005)
R. Lee Buckler: How RepliCel Is Harnessing the Awesome Power of Cell Therapy
Marketwired - Mon Nov 10, 8:15AM CST
Regenerative medicine and cell therapies hold possibilities for achieving near miracles in a multitude of indications, from life-saving treatments to aesthetic applications. RepliCel Life Sciences Inc. (TSX VENTURE: RP) (OTCQB: REPCF) is tackling a mix of medical and cosmetic issues that include hair regeneration, repair of painful and debilitating tendon injuries and rejuvenation of damaged skin. In this interview with The Life Sciences Report, R. Lee Buckler, the company's new vice president of business and corporate development, discusses his firm's innovative technology platform and the upcoming milestones that could affect its shares.
RP.VN: 0.380 (-0.005)
RepliCel Submits Clinical Trial Application to Health Canada for Its Chronic Achilles Tendinosis Trial
Marketwired - Wed Oct 29, 7:07AM CDT
RepliCel Life Sciences Inc. (TSX VENTURE: RP)(OTCQB: REPCF), a clinical stage regenerative medicine company focused on the development of autologous cell therapies, today announced the submission of a Clinical Trial Application to Health Canada requesting clearance to initiate a Phase 1/2 clinical trial investigating the use of RCT-01 to treat patients suffering from chronic Achilles tendinosis.
RP.VN: 0.380 (-0.005)
RepliCel to Present Commercial and Clinical Update at BioJapan 2014 World Business Forum
Marketwired - Thu Oct 09, 7:03AM CDT
RepliCel Life Sciences Inc. (OTCQB: REPCF)(TSX VENTURE: RP), a clinical stage regenerative medicine company focused on the development of autologous cell therapies will be making two presentations at the BioJapan World Business Forum at the Yokohama Convention Centre in Yokohama, Japan.
RP.VN: 0.380 (-0.005)
RepliCel Life Sciences Adds Industry Specialist to Management Team
Marketwire - Tue Oct 07, 7:06AM CDT
RepliCel Life Sciences Inc. (OTCQB: REPCF)(TSX VENTURE: RP), a clinical stage regenerative medicine company focused on the development of autologous cell therapies, today announced the appointment of industry specialist, R. Lee Buckler, to the position of Vice President, Business and Corporate Development.
RP.VN: 0.380 (-0.005)
RepliCel Life Sciences to Present at 11th Annual Phacilitate Cell & Gene Therapy Forum in Washington, DC
PR Newswire - Tue Jan 20, 6:00AM CST
RepliCel Life Sciences Inc. (TSX.V: RP) (OTCQB: REPCF), a clinical stage regenerative medicine company focused on the development of autologous cell therapies, announced today that CEO, David Hall, and VP of Business and Corporate Development, Lee Buckler, will both be presenting at Phacilitate Cell & Gene Therapy Forum 2015. The forum will take place January 26-28th, at the Grand Hyatt in Washington, DC. As part of the conference's opening plenary session, Lee Buckler will be co-presenting at 9:20AM (ET) on January 26, a summary of the past year's most notable events in cell and gene therapy as well as a global snapshot of recently approved cell and gene therapy products and late-stage clinical programs. At 4:45PM (ET) on January 26, David Hall will address attendees of the Cell & Gene Therapy track reviewing Japan's national framework of support for the regenerative medicine industry and what that means for foreign cell therapy companies, like RepliCel, actively engaged in doing business with partners in Japan. At 3:10PM (ET) on January 27, Mr. Hall will give a similar presentation to the attendees of the Stem Cells as Discovery & Research Tools track.
RP.VN: 0.380 (-0.005)
RepliCel Life Sciences to Present at Biotech Showcase 2015 in San Francisco
PR Newswire - Wed Jan 07, 7:00AM CST
Meetings focused on investors, analysts, and potential partners for RCS-01 and RCT-01 cell therapies
RP.VN: 0.380 (-0.005)
Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness
PR Newswire - Mon Dec 22, 6:00AM CST
RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: RP), a clinical stage regenerative medicine company focused on the development of autologous cell therapies, announced today the publication of a paper out of the University of Calgary in conjunction with co-authors from Kyoto University and the University of North Carolina, which further validates the company's ongoing clinical research using dermal sheath cup (DSC) cells to reverse the effects of pattern baldness.
RP.VN: 0.380 (-0.005)
RepliCel Life Sciences to Present at World Stem Cell Summit 2014
Marketwired - Tue Dec 02, 7:07AM CST
RepliCel Life Sciences Inc. (TSX VENTURE: RP) (OTCQB: REPCF), a clinical stage regenerative medicine company focused on the development of autologous cell therapies, announces that its Vice President of Business and Corporate Development, R. Lee Buckler, will present updated clinical trial programs for its chronic tendinosis (RCT-A-01), sun damaged and aging skin (RCS-01), and pattern hair loss (RCH-01) products at the World Stem Cell Summit 2014 in San Antonio, Texas on December 4th at 9:00 am (CT) in conference room 3-4 at the Marriott Rivercenter. At other times during the conference, he will also participate in two different panel discussions covering industry-specific topics and lead an industry roundtable discussion.
RP.VN: 0.380 (-0.005)
RepliCel gets go ahead for clinical trial in Canada
Seeking Alpha - at Seeking Alpha - Mon Dec 01, 11:46AM CST
RepliCel Life Sciences Receives Health Canada Clearance for Clinical Trial in Patients with Chronic Achilles Tendinosis
Marketwired - Mon Dec 01, 6:01AM CST
RepliCel Life Sciences Inc. (TSX VENTURE: RP)(OTCQB: REPCF), a clinical stage regenerative medicine company focused on the development of autologous cell therapies, today announced that it has received a No Objection Letter from Health Canada providing its clearance to proceed with the Company's proposed phase 1/2 clinical trial investigating the use of RCT-01 to treat patients suffering from chronic Achilles tendinosis. The study entitled, "A randomized, double-blind, placebo-controlled, single-centre study to evaluate the efficacy and safety of RCT-01 in men and women with unilateral, chronic Achilles tendinosis" (known as the "ReaCT" study), investigates the potential of RCT-01 to treat chronic tendon injury. The ReaCT study has been submitted to the University of British Columbia (UBC) Clinical Ethics Review Board (CREB) for its review and required approval prior to study initiation at the University of British Columbia Hospital.
RP.VN: 0.380 (-0.005)
RepliCel Announces 2014 Third Quarter Financial Results
Marketwired - Wed Nov 26, 6:01AM CST
RepliCel Life Sciences Inc. (the "Company" or "RepliCel"
(TSX VENTURE: RP) (OTCQB: REPCF), a clinical stage regenerative medicine company focused on the development of autologous cell therapies, today announced its operational and financial results for the third quarter ended September 30, 2014. All amounts included in this news release are expressed in Canadian dollars unless otherwise indicated. The Company's financial statements and management report are available at www.sec.gov, www.sedar.com and at www.replicel.com. RP.VN: 0.380 (-0.005)
R. Lee Buckler: How RepliCel Is Harnessing the Awesome Power of Cell Therapy
Marketwired - Mon Nov 10, 8:15AM CST
Regenerative medicine and cell therapies hold possibilities for achieving near miracles in a multitude of indications, from life-saving treatments to aesthetic applications. RepliCel Life Sciences Inc. (TSX VENTURE: RP) (OTCQB: REPCF) is tackling a mix of medical and cosmetic issues that include hair regeneration, repair of painful and debilitating tendon injuries and rejuvenation of damaged skin. In this interview with The Life Sciences Report, R. Lee Buckler, the company's new vice president of business and corporate development, discusses his firm's innovative technology platform and the upcoming milestones that could affect its shares.
RP.VN: 0.380 (-0.005)
RepliCel Submits Clinical Trial Application to Health Canada for Its Chronic Achilles Tendinosis Trial
Marketwired - Wed Oct 29, 7:07AM CDT
RepliCel Life Sciences Inc. (TSX VENTURE: RP)(OTCQB: REPCF), a clinical stage regenerative medicine company focused on the development of autologous cell therapies, today announced the submission of a Clinical Trial Application to Health Canada requesting clearance to initiate a Phase 1/2 clinical trial investigating the use of RCT-01 to treat patients suffering from chronic Achilles tendinosis.
RP.VN: 0.380 (-0.005)
RepliCel to Present Commercial and Clinical Update at BioJapan 2014 World Business Forum
Marketwired - Thu Oct 09, 7:03AM CDT
RepliCel Life Sciences Inc. (OTCQB: REPCF)(TSX VENTURE: RP), a clinical stage regenerative medicine company focused on the development of autologous cell therapies will be making two presentations at the BioJapan World Business Forum at the Yokohama Convention Centre in Yokohama, Japan.
RP.VN: 0.380 (-0.005)
RepliCel Life Sciences Adds Industry Specialist to Management Team
Marketwire - Tue Oct 07, 7:06AM CDT
RepliCel Life Sciences Inc. (OTCQB: REPCF)(TSX VENTURE: RP), a clinical stage regenerative medicine company focused on the development of autologous cell therapies, today announced the appointment of industry specialist, R. Lee Buckler, to the position of Vice President, Business and Corporate Development.
RP.VN: 0.380 (-0.005)
(0)
(0)Scroll down for more posts ▼